Ifrah Financial Services Inc. Has $462,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Ifrah Financial Services Inc. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 6.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,604 shares of the medical research company’s stock after selling 110 shares during the period. Ifrah Financial Services Inc.’s holdings in Amgen were worth $462,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Briaud Financial Planning Inc acquired a new position in Amgen in the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. acquired a new position in Amgen in the 4th quarter worth about $29,000. OFI Invest Asset Management acquired a new position in Amgen in the 3rd quarter worth about $26,000. Planned Solutions Inc. acquired a new position in Amgen in the 4th quarter worth about $30,000. Finally, Providence Capital Advisors LLC acquired a new position in Amgen in the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 11.8 %

NASDAQ:AMGN traded up $32.90 on Friday, hitting $311.29. The stock had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The business’s fifty day moving average is $274.95 and its 200 day moving average is $281.50. The company has a market cap of $166.97 billion, a PE ratio of 44.47, a P/E/G ratio of 2.69 and a beta of 0.60. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 145.62% and a net margin of 12.74%. The company’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.98 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Morgan Stanley increased their price target on Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday. Royal Bank of Canada decreased their price target on Amgen from $332.00 to $328.00 and set an “outperform” rating for the company in a research note on Friday. BMO Capital Markets increased their price target on Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research note on Friday. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Finally, UBS Group increased their price target on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $305.05.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.46% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.